DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
A PHASE 2, MULTICENTER, OPEN-LABEL, 2- COHORT STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A), AN ANTI-HER2 ANTIBODY DRUG CONJUGATE (ADC), FOR HER2-OVER-EXPRESSING OR -MUTATED, UNRESECTABLE AND/OR METASTATIC NONSMALL CELL LUNG CANCER (NSCLC)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
If you are considering taking part in a clinical trial, talk with your SCCA team about the pros and cons. Discuss what you learn with your health care providers, family and trusted friends. See also the Patient Guide to Clinical Trials.